Medicines
MedPage Today(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...
- FDA Approves Infilbray (venglustat) to Treat Neurological Manifestations of Type 3 Gaucher Disease
Drugs.comParis, November 18, 2026. The US Food and Drug Administration has approved Infilbray (venglustat), a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, for the treatment of neurological manifestations...
- FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival
Medical XpressResearchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare and rapidly fatal pediatric neurode…
- Ex-boxer Goran Gogic pleads guilty to drug charge, faces at least 10 years in prison
ABC NewsFormer heavyweight boxer Goran Gogic has pleaded guilty to a drug charge and likely faces 10-20 years in prison
- STAT+: 7 burning questions about the FDA’s post-Overton future
STATSTAT tackles the most important questions about the FDA's uncertain future.
- Tiny magnets deep inside the brain could transform Parkinson’s treatment
ScienceDailyScientists have developed a new technique that uses magnetic nanoparticles to stimulate deep brain regions, dramatically improving Parkinson’s-like movement problems in mice without permanently implanted electrodes. The breakthrough could pave the way for les…
More Medicines
- White House drops its nominee for FDA commissioner
CBS News
- White House drops Heidi Overton’s FDA nomination after Republicans raise concerns
NBC News
- ‘A Hard Time’ as Federal Cuts Hobble Efforts To Stop Overdoses From Tainted Drugs
KFF Health News
- Widely used antidepressant outperformed by 3 other drugs in major study of 30,000 people
Fox News
- Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Drugs.com
- Acupuncture‑like treatment linked to sustained weight loss in new study
Medical Xpress
- Neanderthal DNA and Schizophrenia; Ayahuasca for PTSD; GLP-1 Reduced Binge Eating
MedPage Today
- Trump administration will fund new research on controversial psychedelic drug ibogaine
ABC News
Top Medicines stories
More Medicines stories
Latest Medicines headlines
- Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
- White House Yanks Pick for FDA Chief
- STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
- FDA Adds Another Player in ALK-Positive Lung Cancer
- Laboratoires Pierre Fabre Announce FDA Fast Track Designation for Elticertinib in NSCLC
- FDA Grants Accelerated Approval to Nelkarmi (neladalkib) for Previously-Treated Advanced ALK-Positive Non-Small Cell Lung Cancer




















